Hikma and FAES Farma enter into exclusive licensing agreement for the commercialisation of Bilastine tablets in the US
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Investegate |Hikma Pharmaceutical Announcements | Hikma Pharmaceutical: Bio-Thera and Hikma announce exclusive agreement
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Hikma appoints Patrick Genestin to lead Generics Business Development
News provided by
Share this article
Share this article
LONDON, June 9, 2021 /PRNewswire/ Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that Patrick Genestin has been appointed Vice President, Business Development, Generics. Mr. Genestin brings to Hikma more than 25 years of experience in the pharmaceutical industry as a results-driven executive with strong financial, business development and M&A experience. He will be based at the company s US headquarters in Berkeley Heights, NJ.
In this role, Mr. Genestin is responsible for driving pipeline strategy and identifying new growth opportunities for Hikma s Generics business, including leading the execution of licensing and M&A deals, proactively identifying business development opportunities and maintaining and growing Hikma s contract manufacturing (CMO) business.
A more powerful naloxone is on the way. The question is whether it’s needed. Lenny Bernstein With deaths from opioids soaring again, the Food and Drug Administration last month approved a more powerful version of the fast-acting antidote naloxone, an emergency medicine that restores breathing halted by overdoses of fentanyl, heroin or oxycodone. In approving just the second version of the lifesaving nasal spray, the FDA allowed a pharmaceutical company to double the strength of the product, from the 4 -milligram doses available now to 8 milligrams of the ingredient in each dose. But there is widespread disagreement about the value of more potent naloxone.